Retrospective analysis of primary patency of vascular access maturity: a single centre experience at HTAA, Kuantan, Malaysia

Introduction Arteriovenous stula (AVF) has been proven to be the best vascular access for the purpose of haemodialyis due to its’ longevity and robustness. Unfortunately, despite of its’ popularity in Malaysia, there is a limited local data being published. HTAA is a main referral center for AVF creation for the east coast of Malaysia. We examined our data for primary patency rate and possible factors that may associates with it. Methods Patients who underwent AVF creation created by a single surgeon from July 2012 to July 2013 in Hospital Tengku Ampuan Afzan (HTAA), Kuantan were identi ed using theatre list and also logbook. Data were collected retrospectively from the patients’ medical notes. A total of 89 patients were identi ed. Primary patency rate is being assessed at 6 weeks. Statistical analysis performed using SPSS® v20. Results The patient’s median age of the patients was 53 years with a slight male predominance (53%). Majority of the subjects have no history of tobacco use (71.4%). The Malays make up the majority in ethnicity (79.6%). 53.1% and 18.4% have underlying diabetes mellitus and obesity respectively. Brachio-cephalic stulas (BCF) are the majority of AVF (71.4%) that were created. 78% of our patients had already been diagnosed with ESRF and 59% was already on dialysis upon AVF creation. 57.1% of the subjects are statins users. The mean diameters of artery and veins are 2.56mm and 2.94mm respectively. Our primary patency rate is 87.8%. Multivariate analysis shows no signi cance between the demographics and maturity but a suggestive association of venous diameter and statins with primary patency rate with p values of 0.06 and 0.07 respectively. Conclusion This study described a comparable success rate of AVF creation at our centre in to other published data. We have identi ed, venous diameter and statins use have a positive trend with primary patency rate of our AVF in a multivariate analysis.